These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11082166)

  • 1. Cushing, cortisol, and cardiovascular disease.
    Whitworth JA; Mangos GJ; Kelly JJ
    Hypertension; 2000 Nov; 36(5):912-6. PubMed ID: 11082166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cushing syndrome. III: Cortisol or glucocorticoid excess].
    Ziegler R
    Dtsch Med Wochenschr; 1993 Aug; 118(32):1163-4. PubMed ID: 8354139
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular consequences of cortisol excess.
    Whitworth JA; Williamson PM; Mangos G; Kelly JJ
    Vasc Health Risk Manag; 2005; 1(4):291-9. PubMed ID: 17315601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired vasodilation and nitric oxide synthase activity in glucocorticoid-induced hypertension.
    Mitchell BM; Webb RC
    Biol Res Nurs; 2002 Jul; 4(1):16-21. PubMed ID: 12363278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases.
    Torpy DJ; Mullen N; Ilias I; Nieman LK
    Ann N Y Acad Sci; 2002 Sep; 970():134-44. PubMed ID: 12381548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 24-hour profiles of blood pressure and heart rate in Cushing's syndrome. Evidence for differential control of cardiovascular variables by glucocorticoids.
    Panarelli M; Terzolo M; Piovesan A; Osella G; Paccotti P; Pinna G; Angeli A
    Ann Ital Med Int; 1990; 5(1):18-25. PubMed ID: 2206764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoids and hypertension in man.
    Whitworth JA; Kelly JJ; Brown MA; Williamson PM; Lawson JA
    Clin Exp Hypertens; 1997; 19(5-6):871-84. PubMed ID: 9247761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cortisol and hypertension.
    Kelly JJ; Mangos G; Williamson PM; Whitworth JA
    Clin Exp Pharmacol Physiol Suppl; 1998 Nov; 25():S51-6. PubMed ID: 9809193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of glucocorticoid-induced hypertension.
    Saruta T
    Hypertens Res; 1996 Mar; 19(1):1-8. PubMed ID: 8829818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surviving ectopic Cushing's syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing's disease during long-term follow-up.
    Osswald A; Deutschbein T; Berr CM; Plomer E; Mickisch A; Ritzel K; Schopohl J; Beuschlein F; Fassnacht M; Hahner S; Reincke M
    Eur J Endocrinol; 2018 Aug; 179(2):109-116. PubMed ID: 29875286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid excess syndromes causing hypertension.
    Krakoff LR
    Cardiol Clin; 1988 Nov; 6(4):537-45. PubMed ID: 3067845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome.
    Giordano R; Picu A; Broglio F; Bonelli L; Baldi M; Berardelli R; Ghigo E; Arvat E
    Pituitary; 2004; 7(4):243-8. PubMed ID: 16132204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension in Cushing's syndrome.
    Magiakou MA; Smyrnaki P; Chrousos GP
    Best Pract Res Clin Endocrinol Metab; 2006 Sep; 20(3):467-82. PubMed ID: 16980206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ambulatory Arterial Stiffness Indexes in Cushing's Syndrome.
    Battocchio M; Rebellato A; Grillo A; Dassie F; Maffei P; Bernardi S; Fabris B; Carretta R; Fallo F
    Horm Metab Res; 2017 Mar; 49(3):214-220. PubMed ID: 28226362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid action and the clinical features of Cushing's syndrome.
    Yanovski JA; Cutler GB
    Endocrinol Metab Clin North Am; 1994 Sep; 23(3):487-509. PubMed ID: 7805650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications.
    Isidori AM; Graziadio C; Paragliola RM; Cozzolino A; Ambrogio AG; Colao A; Corsello SM; Pivonello R;
    J Hypertens; 2015 Jan; 33(1):44-60. PubMed ID: 25415766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid-induced renal vasodilatation is mediated by a direct renal action involving nitric oxide.
    De Matteo R; May CN
    Am J Physiol; 1997 Dec; 273(6):R1972-9. PubMed ID: 9435651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion.
    Tomlinson JW; Draper N; Mackie J; Johnson AP; Holder G; Wood P; Stewart PM
    J Clin Endocrinol Metab; 2002 Jan; 87(1):57-62. PubMed ID: 11788623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man.
    Laue L; Chrousos GP; Loriaux DL; Barnes K; Munson P; Nieman L; Schaison G
    J Clin Endocrinol Metab; 1988 Feb; 66(2):290-3. PubMed ID: 2828406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide-dependent renal vasodilatation is not altered in rat with rHuEpo-induced hypertension.
    Migliori M; Taccola D; Panichi V; De Pietro S; Andreini B; Di Benedetto A; Filippi C; Palla R; Giovannini L
    Kidney Blood Press Res; 1999; 22(3):140-5. PubMed ID: 10394113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.